• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

    4/21/25 7:00:00 AM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email

    PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.

    Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

    An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

    About Amicus Therapeutics

    Amicus Therapeutics (NASDAQ:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company's website at www.amicusrx.com, and follow on X and LinkedIn.

    CONTACT:

    Investors:

    Amicus Therapeutics

    Andrew Faughnan

    Vice President, Investor Relations

    [email protected]

    (609) 662-3809

    Media:

    Amicus Therapeutics

    Diana Moore

    Head of Global Corporate Affairs and Communications

    [email protected]

    (609) 662-5079

    FOLD–G



    Primary Logo

    Get the next $FOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    2/24/2022$16.00 → $14.00Outperform
    SVB Leerink
    More analyst ratings

    $FOLD
    SEC Filings

    See more
    • SEC Form S-8 filed by Amicus Therapeutics Inc.

      S-8 - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      6/5/25 4:46:04 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)

      6/5/25 4:01:43 PM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Amicus Therapeutics Inc.

      SCHEDULE 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)

      5/15/25 9:30:38 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care